Extract

To the Editor—I enjoyed reading the review of the current status of granulocyte transfusion therapy for infectious diseases by Hübel et al. [1]. Given the unproven potential of granulocyte transfusion therapy, the risks to the donor need to be carefully considered. Reports of spontaneous splenic rupture in healthy donors pretreated with granulocyte colony-stimulating factor (G-CSF) [2–4 ] and of the development of serious infections in 2 healthy donors immediately after stem-cell mobilization with the use of G-CSF [5] are of concern. These observations ought to temper the rekindled enthusiasm in the clinical use of granulocyte transfusion therapy in adults

You do not currently have access to this article.